The multicenter open-label ATTIRE study by China et al. found that targeted albumin infusion in patients hospitalized with liver cirrhosis and serum albumin levels < 30 g/L did not decrease the risk of onset of infection, acute kidney injury, or death [29]. The gene discussed is ALB; the disease is infection.